fx1_lrg

Credit:Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones.

Ferroptosis, a form of regulated cell death driven by iron-dependent lipid peroxidation, has emerged as a crucial mechanism in various physiological and pathological processes, including cancer development and progression. Understanding the regulation of ferroptosis is essential for developing targeted therapies that exploit this pathway to selectively eliminate cancer cells. While the roles of well-established ferroptosis regulators like GPX4 and FSP1 have been extensively studied, recent research has unveiled novel players in this complex regulatory network. One such discovery is the identification of membrane-bound O-acyltransferase domain-containing 1 and 2 (MBOAT1/2) as novel ferroptosis regulators with intriguing connections to sex hormones.

The groundbreaking study by Liang et al. utilized a combination of genetic screening and functional assays to uncover MBOAT1/2 as critical regulators of ferroptosis. The researchers began by investigating cells deficient in GPX4, a key ferroptosis inhibitor, and subjected them to two parallel positive selection screens. One screen involved resistance to a covalent GPX4 inhibitor (RSL3), and the other involved resistance to cysteine starvation, a condition known to induce ferroptosis. Through these screens, they identified seven sgRNAs that promoted survival in both settings.

Further investigation revealed that five of these sgRNAs encoded known ferroptosis regulators, but two were novel: MBOAT2 and PLA2G2F. To determine the role of these proteins in ferroptosis, the researchers generated inducible GPX4-FSP1 double-deficient HT1080 cells, which are highly susceptible to ferroptosis. Overexpression of MBOAT2, but not PLA2G2F, effectively rescued these cells from ferroptosis, as evidenced by crystal violet staining. This finding established MBOAT2 as a potent inhibitor of ferroptosis, independent of GPX4 and FSP1.

Subsequent experiments elucidated the mechanism by which MBOAT2 inhibits ferroptosis. The researchers found that MBOAT2 required monounsaturated fatty acids (MUFAs) from either endogenous or exogenous sources to function. MBOAT2-dependent inhibition of ferroptosis was associated with phospholipid remodeling, suggesting that MBOAT2 plays a role in modifying cellular membranes to protect against lipid peroxidation.

Further studies extended these findings to MBOAT1, a closely related acyltransferase. Similar to MBOAT2, MBOAT1 also functioned as an inhibitor of ferroptosis, utilizing MUFAs and promoting phospholipid remodeling. These findings indicated that the MBOAT system, encompassing both MBOAT1 and MBOAT2, was a critical regulator of ferroptosis, independent of GPX4 and FSP1.

The study also revealed a fascinating link between sex hormones and MBOAT expression. Liang et al. demonstrated that MBOAT2 was upregulated in prostate cancer cells upon activation of the androgen receptor (AR), while MBOAT1 was regulated downstream of the estrogen receptor alpha (ERα) in breast cancer cells. This suggested that sex hormones played a role in promoting the expression of MBOAT proteins, potentially conferring resistance to ferroptosis in cancer cells.

The discovery of MBOAT1/2 as ferroptosis regulators with sex hormone connections opens up exciting avenues for future research and potential therapeutic applications.

  1. Targeting MBOAT1/2 in Cancer Therapy:

Given their role in inhibiting ferroptosis and their regulation by sex hormones, MBOAT1/2 present attractive targets for cancer therapy. Developing inhibitors of MBOAT1/2 could sensitize cancer cells to ferroptosis, potentially leading to the development of novel anticancer agents. This approach could be particularly effective in hormone-driven cancers, where the interplay between sex hormones and MBOAT expression may contribute to cancer progression.

  1. Understanding Sex Differences in Ferroptosis Sensitivity:

The connection between sex hormones and MBOAT expression raises intriguing questions about sex differences in ferroptosis sensitivity. Further research is needed to elucidate the precise mechanisms underlying these differences and explore their implications in various diseases, including cardiovascular diseases and neurodegenerative disorders.

  1. Exploring the Role of MBOATs in Other Pathologies:

While the study focused on cancer, the potential role of MBOAT1/2 in other diseases warrants further investigation. Given their involvement in lipid metabolism and ferroptosis regulation, MBOAT1/2 could play a role in various pathologies, including metabolic disorders, inflammatory diseases, and neurodegenerative conditions.

  1. Investigating the Interplay Between MBOATs and Other Ferroptosis Regulators:

Understanding how MBOAT1/2 interact with other known ferroptosis regulators like GPX4 and FSP1 is crucial for developing a comprehensive understanding of ferroptosis regulation. Further research is needed to explore the complex network of interactions between these proteins and how they collectively control ferroptosis in different contexts.

The discovery of MBOAT1/2 as novel ferroptosis regulators with sex hormone connections represents a significant advancement in our understanding of this complex process. This discovery not only expands the repertoire of known ferroptosis regulators but also opens up exciting opportunities for targeted cancer therapy and the exploration of sex differences in ferroptosis sensitivity. Further research is needed to fully understand the mechanisms and implications of MBOAT1/2 regulation and their potential role in various diseases.

Reference:

  1. Liang D, Feng Y, Zandkarimi F, Wang H, Zhang Z, Kim J, Cai Y, Gu W, Stockwell BR, Jiang X. Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones. Cell. 2023 Jun 22;186(13):2748-2764.e22.

  2. Belavgeni A, Tonnus W, Linkermann A. Cancer cells evade ferroptosis: sex hormone-driven membrane-bound O-acyltransferase domain-containing 1 and 2 (MBOAT1/2) expression. Signal Transduct Target Ther. 2023 Sep 8;8(1):336.